Showing results (381-390 of 436) with videos related to
Sort By:
Pageof 44
Molecular Cancer Therapeutics|September 3, 2009
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myelomaFrits van Rhee, Susann M Szmania, Myles Dillon, et al.Nuclear Medicine and Biology|October 9, 2007
Challenges in clinical studies with multiple imaging probesKenneth A Krohn, Finbarr O'Sullivan, John Crowley, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2005
International staging system for multiple myelomaPhilip R Greipp, Jesus San Miguel, Brian G M Durie, et al.Journal of Clinical Medicine|March 25, 2022
Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital AdmissionKristin Larsen, Horace Spencer, Meera Mohan, et al.Haematologica|March 16, 2012
Highly activated and expanded natural killer cells for multiple myeloma immunotherapyTarun K Garg, Susann M Szmania, Junaid A Khan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2003
Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504David R Gandara, Kari Chansky, Kathy S Albain, et al.Nature Communications|January 13, 2021
The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myelomaEileen M Boyle, Shayu Deshpande, Ruslana Tytarenko, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2009
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124Primo N Lara, Ronald Natale, John Crowley, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committeeLesley Seymour, S Percy Ivy, Daniel Sargent, et al.Blood|May 23, 2018
The presence of large focal lesions is a strong independent prognostic factor in multiple myelomaLeo Rasche, Edgardo J Angtuaco, Terri L Alpe, et al.Pageof 44